Clinical Trial: A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.

U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07778498) titled 'A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.' on Aug. 09.

Brief Summary: The goal of this clinical trial is to evaluate whether TJ102, an investigational antibody-drug conjugate (ADC), can safely and effectively treat patients with advanced ovarian or other solid tumors. The main objectives of this study are : * To Determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) of TJ102 * to show preliminary antitumor activity in patients with advanced ovarian or other solid tumors. Participants will: * Receive intravenous ...